Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 372320Orphan Drug2 approvals2 trials

Curocell Inc.

Official website

Founded in 2016, Curocell develops OVIS™ CAR-T therapies and filed for Korean approval of its CD19 therapy Limkato (CRC01) in December 2024.

As of 2026-10-10, Curocell Inc. has 1 Korean MFDS drug approval, 6 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Curocell, founded in 2016 and listed on KOSDAQ in 2023, is a cell and gene therapy company developing multiple CAR-T pipelines. Its lead product is Limkato (generic name anbalcabtagene autoleucel, development code CRC01), a next-generation CD19 CAR-T therapy built on Curocell's proprietary OVIS™ CAR-T technology, alongside pipelines in hematologic, solid tumor, and allogeneic CAR-T. Curocell plans direct production and sales in Korea and licensing or partnering overseas; for Limkato's DLBCL indication it filed for marketing approval with Korea's MFDS in December 2024 and for drug reimbursement review with HIRA in February 2025, targeting a 2026 launch, while its adult ALL indication is in Phase 1 targeting a 2027 launch.

Products & technology

  • LimkatoCD19 CAR-T cell therapy (generic name anbalcabtagene autoleucel, code CRC01) for relapsed/refractory large B-cell lymphoma including DLBCL, HGBL, and PMBCL

Regulatory approvals

data.go.kr

1 Orphan Drug designations · 2024 / 1 Korean MFDS drug approvals · 2026

  • Orphan주사제2024-12-24
    Orphan Drug designation · in development20240221453
  • MFDS drugRIMQARTO (anbalcabtagene autoleucel)2026-04-29
    Drug · Prescription · Approval202601287

Clinical trials

data.go.kr

2 MFDS clinical trial authorisations · 2021–2025 (Phase 1/2 2)

  • Phase 1/2CRC012025-07-31

    1 trial site

  • Phase 1/2CRC012021-02-18

    10 trial sites

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

CRC01 (anbalcabtagene autoleucel, 림카토주) · 거대B세포림프종(DLBCL·HGBL·PMBCL 포함) 등 재발성·불응성 B세포 림프종 성인 환자 · 품목허가 심사 중 · Last patient dosed Oct 2023; final clinical study report (CSR) received May 2024; MFDS fast-track and customized review designation Aug 2024; marketing authorization filed Dec 2024; drug reimbursement review filed with HIRA Feb 2025; targeting 2026 launch. Trials conducted at Samsung Medical Center, Seoul National University Hospital, Asan Medical Center, National Cancer Center, Pusan National University Hospital, and Chonnam National University Hwasun Hospital.

CRC01 (anbalcabtagene autoleucel) · 재발성 또는 불응성 급성림프모구성백혈병(B-cell ALL) 성인 환자 · 임상 1상 (2상 전환 가능) · In Phase 1 under MFDS IND approval; a 2025 IND amendment approved initiation of Phase 2. Targeting 2027 launch.

CRC01 (anbalcabtagene autoleucel) · 심각한 불응성 자가면역질환(전신홍반성루푸스, SLE) 환자 · Listed as a target patient population; the specific clinical stage is not disclosed in the source text.

혈액암·고형암·동종유래 CAR-T 파이프라인 · Disclosed as holding additional pipelines in hematologic, solid tumor, and allogeneic CAR-T beyond CD19 CAR-T, but no specific program names, indications, or clinical stages are given in the source text.

Key disclosures

KRX KIND via OpenDART
Show 1 more events

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 16 more patents

AI reads

MAA server logs · IP-verified
75
Times AI engines pulled Curocell Inc.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

6
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

69
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

11
live 0
Last 7 days
54
live 2
Last 30 days
75
live 6
All time
  • OpenAIChatGPT-Userlive6
  • OpenAIOAI-SearchBot59
  • PerplexityPerplexityBot5
  • GoogleGoogleOther2
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 25, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Curocell Inc. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition